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ABSTRACT
Background: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by toxicity.
Preliminary studies have suggested an association between plasma concentrations of sorafenib and its
main metabolite (M2) and clinical outcomes. This study aimed to validate these findings and establish
target values for sorafenib trough concentrations.
Methods: Patients with advanced HCC were prospectively recruited within a multicenter phase II study
(SORAMIC). Patients with blood samples available at trough level were included for this pharmacoki-
netic (PK) substudy. Trough plasma concentrations of sorafenib and its main metabolite (M2) were
associated with sorafenib-related toxicity and overall survival (OS).
Results: Seventy-four patients were included with a median OS of 19.7months (95% CI 16.1–23.3).
Patients received sorafenib for a median of 51weeks (IQR 27–62) and blood samples were drawn after
a median of 25weeks (IQR 10–42). Patients had a median trough concentration of 3217 ng/ml (IQR
2166–4526) and 360ng/ml (IQR 190–593) with coefficients of variation of 65% and 146% for sorafenib
and M2, respectively. Patients who experienced severe sorafenib-related toxicity received a lower aver-
age daily dose (551 vs 730mg/day, p¼ .003), but showed no significant differences in sorafenib (3298
vs 2915 ng/ml, p¼ .442) or M2 trough levels (428 vs 283ng/ml, p¼ .159). Trough levels of sorafenib or
M2 showed no significant association with OS.
Conclusions: In patients with advanced HCC treated with sorafenib, the administered dose, trough
levels of sorafenib or M2, and clinical outcomes were poorly correlated. Toxicity-adjusted dosing
remains the standard for sorafenib treatment.
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Introduction
Hepatocellular carcinoma (HCC) is the most common primary
liver cancer and ranks as the fourth most common cause of
cancer-related death worldwide [1]. Despite surveillance pro-
grams for patients at risk for developing HCC, around 40% of
patients present with advanced-stage HCC that is incurable
and has a poor prognosis. These patients have tumors with
macrovascular invasion, extrahepatic metastases or cancer-
related symptoms. Systemic treatment with sorafenib was
the first therapy to show a survival benefit over placebo
(median of 2–3months) in advanced HCC patients or those
ineligible for locoregional treatment [2,3]. After sorafenib’s
implementation other first- and second-line targeted thera-
pies have been approved [4], but sorafenib remains the
standard of care as first-line treatment for patients with
advanced HCC (Barcelona Clinic Liver Cancer [BCLC-C]) and
preserved liver function [5,6].
There is great variability in sorafenib tolerability and sur-
vival benefit. Sorafenib treatment frequently causes adverse
events (AEs) leading to treatment interruption (44%) or per-
manent discontinuation (11%), whereas objective radiological
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responses to sorafenib are uncommon (2–10%) [3,6]. Survival
outcomes of patients treated with sorafenib can vary from
<3months to more than 3 years [2,3,7]. In the absence of
good predictive biomarkers for response or toxicity to sorafe-
nib, the standard practice is to dose sorafenib at 400mg
twice daily (b.i.d.) orally, adjusted by clinical signs of toxicity
and continued until signs of disease progression.
Prior studies have shown a high degree of interpatient
variability in sorafenib exposure with a coefficient of vari-
ation (CV) ranging between 15 and 91% [8–10]. Preliminary
studies have suggested an association between plasma con-
centrations of sorafenib and toxicity [11–13] and to a lesser
extent with treatment efficacy [12,13]. A Japanese study sug-
gested that the plasma concentration of the pyridine N-oxide
metabolite (M2) of sorafenib, which is the main metabolite
with similar in vitro potency to the parent drug [8], or the
M2/sorafenib ratio of concentrations, had an even stronger
correlation with treatment outcomes [13]. This suggests that
individualized dosing guided by sorafenib pharmacokinetics
(PK) could lead to less underdosing and reduce the toxicity
rates due to overdosing. Moreover, the sorafenib area under
the plasma concentration curve (AUC) has been shown to
decrease significantly during the course of sorafenib treat-
ment [14–17]. Therapeutic drug monitoring (TDM) may allow
treatment personalization and improve the treatment toler-
ability and efficacy. Because the current evidence is prelimin-
ary, consisting of studies with small sample size (n 36) and
heterogeneous exposure parameters (AUC, trough level, max-
imum concentration), no target value of sorafenib plasma
concentration has been defined yet [9,10,18,19]. Therefore,
the present study aimed to validate whether plasma levels of
sorafenib or M2 was associated with toxicity and survival in a
large cohort of patients treated with sorafenib in the context
of the SORAMIC trial [20]. Our study aimed to establish tar-
get values for sorafenib trough concentrations to aid clini-
cians in optimizing sorafenib treatment.
Methods
Study population
This study was a pre-planned PK substudy of the SORAMIC
trial, a prospective, randomized-controlled, phase II trial con-
ducted at 38 sites in 12 countries in Europe and Turkey [20].
The SORAMIC trial consisted of three parts: a diagnostic part,
a curative part and a palliative part [21]. The present study
was performed within the palliative part of SORAMIC, where
patients were randomized to receive sorafenib monotherapy
(standard of care) or selective internal radiation therapy
(SIRT) plus sorafenib [20]. A full list of eligibility criteria for
the palliative part of SORAMIC is shown in Supplementary
Appendix A. In summary, patients were eligible if they had
preserved liver function (Child-Pugh B7), an Eastern
Cooperative Oncology Group performance status (ECOG PS)
2 and unresectable tumors not eligible for curative treat-
ment or Transarterial Chemoembolization (TACE).
Extrahepatic metastases were permitted if patients displayed
liver-dominant disease and did not have pulmonary
metastases. For this PK substudy, eligible patients required
1 blood sample suitable for trough level analysis, as
defined below.
Written informed consent was obtained from each partici-
pant and the study protocol was approved by the institu-
tional review board (IRB).
Sorafenib treatment
In the sorafenib monotherapy arm, sorafenib was started dir-
ectly after randomization, whereas sorafenib was started
3 days after completion of SIRT in the combination therapy
arm. In both groups, patients started with sorafenib at a
dose of 200mg b.i.d. for 1week before increasing the dose
to the target dose of 400mg b.i.d. In case of toxicity, dose
modifications followed pre-defined dosing guidelines
depending on the type and severity of AEs (Supplementary
Figure 1). The lowest accepted dose level (level–2) was
200mg b.i.d. on alternate days. After the resolution of toxic-
ities to grade 0–1, a stepwise dose-escalation was consid-
ered, aiming to maintain the highest tolerable dose level in
each patient. Patients received follow-up every two months
with the recording of all treatment-emergent adverse events
(TEAEs) and routine laboratory assessment. Sorafenib was
continued until unacceptable toxicity or disease progression.
PK sampling and analysis
PK analysis was performed on blood samples (3.5–5mL EDTA
plasma tubes) collected during routine follow-up visits, which
were centrifuged and stored locally at –80 Celsius. The
plasma levels of sorafenib and M2 were analyzed centrally
(AMC Hospital Pharmacy laboratory, Amsterdam, The
Netherlands) using liquid chromatography coupled to tan-
dem mass spectrometry (LC-MS/MS) (Appendix B). With a
sample volume of 100 mL, the sensitivity of LC-MS/MS is suffi-
cient to determine sorafenib levels far below the therapeutic
level with a lower limit of quantification of 20 ng/mL.
Sorafenib is administered orally twice daily, approximately
every 12 h, therefore trough levels were taken just before
sorafenib dosing. Patients were instructed to take sorafenib
without food at least 1 h before or 2 h after a meal. To cor-
rect for discrepancies from planned sampling times, trough
plasma levels of sorafenib and M2 were estimated using the
measured concentrations and time (t) between last sorafenib
dose and PK sampling, based on the first-order kinetics
expression (Supplementary Figure 2A), assuming the half-life
of sorafenib to be 36.5 h [8,22]. Trough levels were calculated
with the following equation:
Trough level at 12hours ¼ Concentration ðtÞ
 eð ln 2=36:5 x ð12tÞÞ:
Samples taken within 4–22 h after sorafenib intake were
used, causing a maximum adjustment of 17% in plasma level
(Supplementary Figure 2B). Steady-state trough levels are
achieved after 1week of sorafenib usage at the same dose
level [8].
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Patients included in this substudy required 1 PK samples
which met the following criteria:
 Blood sample drawn within 4–22 hours following last sor-
afenib intake (trough level)
 Blood sample drawn after 7 consecutive days of sorafe-
nib treatment without dose modifications (steady state)
 The blood sample had measurable sorafenib levels.
In case of multiple trough level samples per patient, the
mean and highest value of trough levels for sorafenib and
M2 were used for analyses.
Outcome measures
This study explored the association between trough
plasma levels of sorafenib and M2 with two main clinical
outcomes: toxicity and overall survival. Adverse
events were recorded according to the Common
Terminology Criteria for Adverse Events (CTCAE) version
4.0. The relationship of each AE to sorafenib was assessed
by the treating physician on a scale from ‘none’(0) to
‘definite’(5). For the toxicity analyses, AEs with a ‘probable’
(4) or ‘definite’ (5) relationship with sorafenib were
included. Overall survival (OS) was calculated from date of
randomization in the SORAMIC trial to date of death or
last follow-up.
Although certain subgroups (age <65, nonalcoholic eti-
ology, no cirrhosis) showed increased OS with SIRT plus sora-
fenib, the main SORAMIC study showed no significant
differences between patients treated with sorafenib mono-
therapy or SIRT plus sorafenib in OS or the occurrence of
treatment-related adverse events [20]. Therefore, both treat-
ment arms were retained in the present substudy, provided
that these treatment subgroups were balanced for parame-
ters factors associated with survival differences (age, nonalco-
holic etiology, cirrhosis) [20].
Statistical analysis
Categorical parameters were described as absolute and
relative counts and continuous parameters as mean with
standard deviation (SD) or medians with interquartile
range (IQR) where appropriate. The correlation between
measurements was expressed using Spearman’s rank cor-
relation test (q). The Kaplan–Meier method was used to
estimate and plot the OS with median and 95% confidence
interval (95% CI). Baseline, treatment and PK characteristics
were compared in subgroups of patients with and without
grade 3–4 sorafenib-related AEs using the Pearson Chi-
Square, Fisher’s exact, Student t-test or Mann–Whitney U-
test. For efficacy, the mean trough levels of sorafenib, M2
and M2/sorafenib ratio were selected for exploratory analy-
ses with OS. For both sorafenib and M2, there are no vali-
dated cutoff values for efficacy or toxicity, although based
on preclinical experience 3750 ng/mL has been proposed
as an appropriate target for sorafenib (parent compound)
[19]. Another study suggested an M2/Sorafenib ratio of
0.13 as optimum cutoff [13]. Therefore, multiple cutoffs
were tested, including quartile-based stratification and
dichotomization of patients according to the 3750 ng/ml
cut-point for sorafenib. The survival rates were compared
using log-rank tests and Cox proportional hazard analysis.
Results
Patient characteristics
Of the 424 patients randomized within the palliative arm of
the SORAMIC trial between 5 January 2011 and 19 April
2016, 141 (33%) underwent PK sampling. Of these, 58
patients were excluded because they lacked a blood sample
at trough level (n¼ 48), there was a recent dose modification
prior to PK sampling (n¼ 7) or sorafenib levels were non-
measurable (n¼ 3) (Figure 1). Consequently, a total of 74
patients were included in this study. The patient characteris-
tics are summarized in Table 1. Twenty-nine (39%) patients
were treated with SIRT plus sorafenib and 45 patients
received sorafenib monotherapy (61%). There were no signifi-
cant baseline differences between these treatment groups,
especially with regard to factors that have been associated
with an increased survival benefit of the addition of SIRT to
sorafenib (age <65, nonalcoholic etiology, non-cirrhosis).
Figure 1. Study flowchart.
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Sorafenib treatment and PK sampling
Median duration of sorafenib administration was 51weeks
(IQR 27–62), which was significantly longer in the sorafenib
monotherapy arm compared with the SIRT plus sorafenib
arm (53 vs 34weeks, p¼ .029). The mean daily dose was
676mg (IQR 453–782). A total of 154 PK samples were suit-
able for trough level analysis, ranging between 1 and 6 sam-
ples per patient and drawn after a median of 25weeks (IQR
10–42) after the start of sorafenib treatment. The trough
level was determined in a single sample in 30 (41%) patients
or, in patients with two (n¼ 19, 26%) or 3 samples (n¼ 25,
34%), the average and highest value was calculated. Patients
had a mean trough level of sorafenib and M2 of 3217 ng/ml
(IQR 2166–4526, range 452–11,995) and 360 ng/ml (IQR
190–593, range 27–6272) with CVs of 65% and 146%,
respectively. There was no significant correlation between
mean daily doses and mean trough levels of sorafenib
(q¼ 0.091, p¼ .439) or M2 (q¼ 0.022, p¼ .851). The highest
measured trough level of sorafenib and M2 in each patient
was 3653 ng/ml (IQR 2318–6083, range 491–11995) and
468 ng/ml (IQR 214–871, range 27–6927), respectively. There
were no significant differences in mean trough levels of sora-
fenib (3258 vs 2745 ng/ml, p¼ .230) or M2 (522 vs 344 ng/ml,
p¼ .089) between patients treated with SIRT plus sorafenib
or sorafenib, respectively.
Association between sorafenib toxicity and
trough levels
The sorafenib-related AEs are summarized in Supplementary
Table 1. The most common AEs were hand-foot syndrome or
rash (43%), diarrhea (38%) and asthenia (28%). There were
no treatment-related deaths, but treatment-related severe
AEs (grade 3–4) were reported in 27 patients (37%). There
were no baseline or clinical differences in patients develop-
ing grade 3–4 AEs (Supplementary Table 2), except that
these patients received a lower daily sorafenib dose (551mg/
day, IQR 409-716) than patients with no or limited toxicity
(730mg/day, IQR 593–788) (p¼ .003), reflecting previous
dose reductions in these patients.
The timing of PK sampling was poorly matched with the
occurrence of AEs: most AEs (45%) occurred in the first
8weeks of treatment, whereas the median time to PK sam-
pling was 25weeks (IQR 10–42) and investigators reported in
only 42/154 PK samples (28%) that the patient had an AE at
that time. In the available samples, there were no significant
differences in trough levels of sorafenib or M2 (mean or
highest) between patients with and without severe (grade
3–4) sorafenib-related toxicity (Figure 2, Supplementary Table
2), suggesting that similar serum levels were present once a
tolerable dose had been identified. There also was no differ-
ence in the M2/sorafenib ratio between patients with and
without severe toxicity (Supplementary Table 2).
Association between survival and trough levels
After a median follow-up period of 50.3months (95% CI
20.9–79.7), 57 of the 74 patients (77%) had died. The median
OS was 19.7months (95% CI 16.1–23.3), which was not sig-
nificantly different between patients treated with SIRT plus
sorafenib or sorafenib monotherapy (p¼ .157)(Supplementary
Figure 3). There were no significant differences in OS based
on the literature suggested cut-point of 3750 ng/ml (Figure
3(A)), or between the different quartiles of trough levels of
sorafenib (Table 2, Figure 3(B)). Similarly, there was no signifi-
cant association between steady-state trough levels of the
M2 metabolite or M2/sorafenib ratio and OS (Table 2,
Figure 3(C,D)).
Discussion
In this multicenter study, the largest prospective PK study of
sorafenib for HCC patients, no significant association was
found between trough values of sorafenib or its main metab-
olite (M2) and treatment outcomes (toxicity and OS). Patients
who underwent dose reduction for severe toxicity had similar
Table 1. Patient characteristics.
Variable PK population (n¼ 74)
Demographics
Age, years – mean (SD) 65 (8.7)
Male sex – no. (%) 66 (89)
BMI – mean (SD) 28 (5.2)
BSA – mean (SD) 2.0 (0.2)
Liver disease
Etiology, multiple possible – no. (%)
HBV 9 (12)
HCV 16 (22)
Alcohol 35 (47)
NAFLD-NASH 13 (18)
Other / Unknown 12 (16)
Cirrhosis – no. (%) 61 (82)
Child-Pugh class – no. (%)
A 72 (97)
B 2 (3)
Tumor parameters
ECOG PS – no. (%)
0 50 (68)
1 24 (32)
Largest tumor size, mm – median (IQR) 52 (31-84)
Multifocal or diffuse no. (%) 67 (84)
Macrovascular invasion – no. (%) 32 (43)
Extrahepatic metastases – no. (%)
Lymph node 6 (8)
Other 3 (4)
BCLC stage – no. (%)
A 0 (0)
B 24 (32)
C 50 (68)
Received prior treatments – no. (%) 35 (47)
Serum tests (median, IQR)
AFP, ng/ml – median (IQR) 29 (6-1525)
Albumin, g/l – mean (SD) 40 (4.7)
Total bilirubin, mmol/L – median (IQR) 12 (9-15)
Treatment details
SORAMIC treatment arm – no. (%)
SIRT plus sorafenib (palliative) 29 (39)
Sorafenib monotherapy 45 (61)
Duration sorafenib treatment, weeks – median (IQR) 51 (27-62)
AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; BMI: body-mass
index; BSA: body-surface area; ECOG PS: Eastern Cooperative Oncology Group
performance status; HBV: hepatitis B virus; HCV: hepatitis C virus; IQR: inter-
quartile range; NAFLD-NASH: Nonalcoholic fatty liver disease-nonalcoholic
steatohepatitis; no: number; PK: pharmacokinetic; SD: standard deviation; SIRT:
selective internal radiation therapy.
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trough levels to patients who tolerated a higher dose, sug-
gesting that toxicity-adjusted dosing leads to similar
trough levels.
Toxicity-adjusted dosing remains the current practice in
sorafenib treatment of advanced HCC. Our study showed
comparable plasma levels and confirmed the large inter-
patient variability in plasma concentrations of sorafenib
(65%) and its M2 metabolite (146%) as shown by prior stud-
ies [9,10,19]. Although the incidence and distribution of sora-
fenib-related toxicity was similar to previous studies [3,23,24],
the present study did not confirm the association between
plasma concentrations of sorafenib and toxicity as suggested
by preliminary studies [11–13,17]. These studies had smaller
sample size (n¼ 12–54), studied a variety of PK parameters
(AUC, peak level, trough level) and all included PK sampling
preceding the toxicity during the first four weeks of treat-
ment as opposed to median sampling time of 25weeks in
this study. As the majority of sorafenib-induced AEs occur
within the first 8weeks of treatment and dose reductions are
performed accordingly, the difference in timing of PK blood
sampling might be a potential explanation for these different
findings. While there was no difference in trough levels in
patients who experienced grade 3–4 AEs, these patients did
receive a lower daily dose compared with patients without
severe toxicity (551 vs 730mg/day, p¼ .003), suggesting that
patients had similar serum levels once a tolerable dose had
been established after dose reductions. These findings are in
accordance with three prior studies, showing a poor associ-
ation between the maximum-tolerated sorafenib dose and
plasma concentration [13,17,25]. For many tyrosine kinase
inhibitors (TKIs), the molecular mechanism of action (target
modulation) poorly correlates with the maximum tolerated
dose [26]. Unlike conventional cytotoxic agents, a clear linear
relationship between increasing dose and toxicity grade is
often not seen in TKIs. This underscores the need for studies
to elucidate the mechanisms driving the onset of sorafenib-
related toxicity.
Regarding treatment efficacy, monitoring plasma concen-
tration is currently not recommended for sorafenib treat-
ment. Based on preclinical studies and the mean sorafenib
exposure in humans, a sorafenib level of 3750 ng/ml was
suggested as a potential target value that needed further
validation [18,19]. In our study, this cutoff showed no signifi-
cant association with OS. Two prior Japanese studies have
analyzed PK (AUC and maximum levels) in relation to OS and
progression-free survival (PFS) [12,13]. Fukudo et al. showed
in 36 patients a trend toward longer OS in patients who
achieved a maximum concentration of >4780 ng/ml [12].
Shimada et al. showed in 25 patients a longer PFS in patients
with an AUCN-oxide >2.0 lg	day/mL and recommended moni-
toring the M2/sorafenib ratio with a cutoff of 0.13 [13]. Our
study did not reveal significant differences in OS between
the different quartiles of sorafenib, M2 trough levels or M2/
sorafenib ratio in patients with advanced HCC. Moreover, the
arbitrary cutoffs suggested by these preliminary studies were
not confirmed in our study. Consequently, the optimal
plasma concentration remains unknown.
For the majority of TKI’s, the value of dose individualiza-
tion using TDM is still exploratory and the dose is only
adjusted in case of intolerable toxicity [19]. The value of
TDM in TKI’s was demonstrated in imatinib treatment for
chronic myeloid leukemia (CML) and gastrointestinal stromal
tumors [27,28]. Imatinib has high response rates in CML
(69–87%) compared with the low rates of objective
responses to sorafenib in HCC (<10%) [3,29]. Advanced HCC
is a complex disease in which the patient’s survival is
impacted by both the tumor biology and severity of the
underlying liver disease. Despite extensive studies, no single
predictive marker with a strong association with survival out-
comes has been identified [30]. Still, refinement of sorafenib
dosing has been shown to be feasible: a lower starting dose
with toxicity-adjusted ramp dosing has been shown to
reduce the toxicity with similar survival outcomes and
improved cost-effectiveness compared to a full-dose strat-
egy [31–33].
A potentially interesting application of TDM could be veri-
fication of the patient’s compliance to treatment. Of all
patients who underwent PK sampling within SORAMIC
(n¼ 141), 36 patients (26%) did not have detectable sorafe-
nib levels despite having reported to have taken sorafenib
Figure 2. Boxplot distribution of mean and highest sorafenib and M2 trough
levels according to the severity sorafenib-related toxicity. Boxes and line repre-
sent 25–75 percentiles and median value, the whiskers are drawn according to
the Tukey method. Outliners are represented by .
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less than a day ago, suggesting treatment noncompliance.
Noncompliance to therapy dosing is a well-recognized prob-
lem in oncology, with estimates for patients taking oral anti-
cancer medications ranging between 10-50%, a finding
which has health economic implication [34].
This study has several limitations. Firstly, (early) PK sam-
pling was not the primary aim nor a mandatory procedure in
the SORAMIC trial. Consequently, not all patients in SORAMIC
underwent PK sampling and patients with a longer duration
of treatment and might have had a higher chance of under-
going (trough level) PK sampling. Sample availability was
mandatory for this PK substudy, causing a selection bias
toward patients with a longer treatment duration and sur-
vival. In addition, the sample size of 74 patients was not suf-
ficient to perform meaningful subgroup analyses with
respect to factors associated with OS in patients treated with
SIRT/sorafenib [20]. Also, few patients had samples available
during the first treatment weeks, so the prognostic value of
plasma concentrations in an early treatment phase could not
be assessed.
Despite these limitations, this is the largest prospective
study investigating the value of trough level PK sampling in
patients treated with sorafenib. Future PK studies in patients
treated with sorafenib or other TKIs should implement early
(i.e., within 4weeks after the start of treatment) PK sampling
and additional blood samples in case of toxicity. There is
accumulating evidence that early sorafenib-related toxicity,
including hand-foot syndrome, diarrhea and hypertension, is
associated with improved OS [35–37]. Therefore, improved
insight into the toxicity-response mechanism and the role of
drug exposure is warranted. More frequent sampling would
allow for more advanced methods of exposure analysis (i.e.,
nonlinear mixed-effects modelling). These models are more
likely to reflect real-life drug exposure compared with (single
sample) through levels.
In conclusion, our study confirmed the large variability in
plasma levels of sorafenib and its main metabolite (M2).
Figure 3. Overall survival according to (A) mean trough plasma level of sorafenib 3750 (21.4months, 95% CI 15.2–27.6) or >3750 ng/ml (19.6months, 95% CI
15.7–23.5), (B) quartiles of trough levels of sorafenib, (C) quartiles of through levels of M2 and D) M2/Sorafenib ratio.
Table 2. Survival according to mean trough levels of sorafenib and
M2 sorafenib.
Group N Median OS, months (95% CI)
Hazard ratio
(95% CI) p-value
Sorafenib – Mean trough plasma level (ng/ml)
2166 18 24.5 (15.3–33.6) 1 Reference
2167–3217 19 19.1 (8.3–29.8) 1.79 (0.85–3.75) .125
3218–4526 19 16.0 (11.7–20.3) 1.55 (0.69–3.46) .288
>4526 18 19.6 (16.1–23.1) 1.53 (0.70–3.33) .288
M2 – Mean trough plasma level (ng/ml)
190 18 19.7 (12.6–26.8) 1 Reference
191–360 19 19.1 (10.4–27.7) 1.08 (0.51–2.32) .837
361–593 19 22.2 (14.2–30.1) 1.39 (0.66–2.94) .393
>593 18 19.8 (7.9–31.7) 1.32 (0.61–2.87) .487
M2/sorafenib ratio
0.13 50 21.4 (15.6–27.2) 1 Reference
>0.13 29 19.8 (11.3–28.3) 1.48 (0.87–2.53) .148
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There was no significant association between steady-state
trough levels of sorafenib or M2 and toxicity or OS. Given
the poor association between administered dose, plasma
concentrations and clinical outcomes, a target plasma con-
centration for sorafenib or M2 cannot be established and
toxicity-adjusted dosing remains the standard for sorafe-
nib treatment.
Acknowledgements
We would like to acknowledge Marloes Vos, research analyst at the
Hospital Pharmacy, for her work in handling and analyzing the
blood samples.
Ethical approval
All procedures performed in studies involving human participants were
in accordance with the ethical standards of the institutional and/or
national research committee and with the 1964 Helsinki declaration and
its later amendments or comparable ethical standards.
Study registration: EudraCT 2009-012576-27, NCT0112 6645
Informed consent: Written informed consent was obtained from all
individual participants included in the study. This study protocol was
approved by the institutional review board (IRB).
Author contributions
TL lead the study, performed data acquisition and analysis, and wrote
the manuscript. TL, QH and RS performed and supervised data analysis.
RBT, OvD, RM, PM, HA, KS, BB, CK, JM, JR and HJK supervised the study,
provided data and clinical input and provided mentorship for the study.
HJK conceived the study design and is the guarantor of the article.
All authors have reviewed and approved the final version of
the manuscript.
Disclosure statement
RBT has served as a speaker for Gore WL, Bayer, and Norgine. He is a
member of the advisory board for Gilead and Norgine. He has received
grants from the Netherlands Organization for Health Research and
Development (ZonMw) and The Netherlands Society for
Gastroenterology (NVGE). OvD has served as a consultant for Cook
Medical. RM has served as an advisor for Bayer, CSL Behring, Merck
Sharp & Dohme, Shire and Zeria (all honoraria/fees paid to the depart-
ment. He has received grants from Bayer, CSL Behring, Shire and
ZonMw. PM reports grants from Bayer, grants from Sirtex, during the
conduct of the study. HA reports lecture fees from Pfizer, Sirtex,
Novartis, GE healthcare and Norgine. BB has served as a member of
advisory boards for Eisai Limited, Celgene, Astex, GenMab, received per-
sonal fees from Bayer, speakers fees from Biocompatibles Ltd and Eisai
Europe Limited (honoraria/fees paid to institution). JR reports grants
from Sirtex Medical, grants from Bayer AG, during the conduct of the
study; personal fees from Sirtex Medical, personal fees from Bayer, per-
sonal fees from Bristol-Myers Squibb, personal fees from LaForce, per-
sonal fees from Roche, personal fees from Lilly Deutschland GmbH,
personal fees from Siemens Healthineers, personal fees from Medison
Pharma, personal fees from MCI Deutschland, personal fees from LIAM
GmbH, outside the submitted work. HJK was member of an advisory
board for Ipsen and Sirtex. He has received grants from the Dutch
Cancer Society (KWF) and an unrestricted research grant from Bayer out-
side the submitted work.
All other authors have declared no conflicts of interest.
Funding
Financial support was provided by Sirtex Medical and Bayer Healthcare.
The study was designed and conducted by academic investigators.
ORCID
Tim A. Labeur http://orcid.org/0000-0002-9988-5077
Regina Schinner http://orcid.org/0000-0002-3082-6570
Peter Malfertheiner http://orcid.org/0000-0001-8439-9036
Holger Amthauer http://orcid.org/0000-0003-4414-0657
Kerstin Sch€utte http://orcid.org/0000-0003-2472-8074
Bristi Basu http://orcid.org/0000-0002-3562-2868
Christiane Kuhl http://orcid.org/0000-0002-7698-9252
Julia Mayerle http://orcid.org/0000-0002-3666-6459
Jens Ricke http://orcid.org/0000-0001-8762-8594
Heinz-Josef Kl€umpen http://orcid.org/0000-0002-7290-1823
References
[1] Jemal A, Ward EM, Johnson CJ, et al. Annual report to the Nation
on the Status of Cancer, 1975–2014, featuring survival. J Natl
Cancer Instit. 2017;109(9). DOI:10.1093/jnci/djx030
[2] Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafe-
nib in patients in the Asia-Pacific region with advanced hepato-
cellular carcinoma: a phase III randomised, double-blind, placebo-
controlled trial. Lancet Oncol. 2009;10(1):25–34.
[3] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hep-
atocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
[4] Montironi C, Montal R, Llovet JM. New Drugs effective in the sys-
temic treatment of hepatocellular carcinoma. Clin Liver Dis. 2019;
14(2):56–61.
[5] EASL clinical practice guidelines: management of hepatocellular
carcinoma. J Hepatol. 2018;69(1):182–236.
[6] Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 2018;29(Supplement_4):iv238–iv255.
[7] Marrero JA, Kudo M, Venook AP, et al. Observational registry of
sorafenib use in clinical practice across Child-Pugh subgroups:
the GIDEON study. J Hepatol. 2016;65(6):1140–1147.
[8] Bayer Schering Pharma AG B, Germany. EU summary of product
characteristics for Nexavar, 21 July 2011.
[9] Klumpen HJ, Samer CF, Mathijssen RH, et al. Moving towards
dose individualization of tyrosine kinase inhibitors. Cancer
Treatment Rev. 2011 ;37(4):251–260.
[10] Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug
monitoring of anticancer drugs part two–targeted therapies. Eur
J Cancer (Oxford, England). 2014;50(12):2020–2036.
[11] Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-
induced toxicity is associated with drug exposure and UGTIA9
genetic polymorphism in patients with solid tumors: a prelimin-
ary study. PLOS One. 2012;7(8):e42875.
[12] Fukudo M, Ito T, Mizuno T, et al. Exposure-toxicity relationship
of sorafenib in Japanese patients with renal cell carcinoma
and hepatocellular carcinoma. Clin Pharmacokinet. 2014;53(2):
185–196.
[13] Shimada M, Okawa H, Kondo Y, et al. Monitoring serum levels of
sorafenib and its N-oxide is essential for long-term sorafenib
treatment of patients with hepatocellular carcinoma. Tohoku J
Exp Med. 2015;237(3):173–182.
[14] Arrondeau J, Mir O, Boudou-Rouquette P, et al. Sorafenib expos-
ure decreases over time in patients with hepatocellular carcin-
oma. Invest New Drugs. 2012;30(5):2046–2049.
[15] Tolcher AW, Appleman LJ, Shapiro GI, et al. A phase I open-label
study evaluating the cardiovascular safety of sorafenib in patients
with advanced cancer. Cancer Chemother Pharmacol. 2011;67(4):
751–764.
ACTA ONCOLOGICA 7
[16] Boudou-Rouquette P, Ropert S, Mir O, et al. Variability of sorafe-
nib toxicity and exposure over time: a pharmacokinetic/pharma-
codynamic analysis. Oncologist. 2012;17(9):1204–1212.
[17] Fucile C, Marenco S, Bazzica M, et al. Measurement of sorafenib
plasma concentration by high-performance liquid chromatog-
raphy in patients with advanced hepatocellular carcinoma: is it
useful the application in clinical practice? A pilot study. Med
Oncol. 2014;32(1):335.
[18] Yu H, Steeghs N, Nijenhuis CM, et al. Practical guidelines for
therapeutic drug monitoring of anticancer tyrosine kinase inhibi-
tors: focus on the pharmacokinetic targets. Clin Pharmacokinet.
2014;53(4):305–325.
[19] Verheijen RB, Yu H, Schellens JH, et al. Practical recommendations
for therapeutic drug monitoring of kinase inhibitors in oncology.
Clin Pharmacol Ther. 2017;102(5):765–776.
[20] Ricke J, Klumpen HJ, Amthauer H, et al. Impact of combined
selective internal radiation therapy and sorafenib on survival in
advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):
1164–1174.
[21] Evaluation of sorafenib in combination with local micro-therapy
guided by Gd-EOB-DTPA enhanced MRI in patients with inoper-
able hepatocellular carcinoma [updated 2 December 2016].
Available from: https://clinicaltrials.gov/ct2/show/study/NCT01
126645.
[22] Di L, Kerns EH. Drug-like properties: concepts, structure design
and methods from ADME to toxicity optimization. Academic
press; 2015.
[23] Howell J, Pinato DJ, Ramaswami R, et al. On-target sorafenib tox-
icity predicts improved survival in hepatocellular carcinoma: a
multi-centre, prospective study. Aliment Pharmacol Ther. 2017;
45(8):1146–1155.
[24] Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic
adverse events predict better outcome in HCC patients treated
with sorafenib. J Hepatol. 2014;61(2):318–324.
[25] Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafe-
nib in patients with metastatic or recurrent sarcomas. JCO. 2009;
27(19):3133–3140.
[26] Takimoto CH. Maximum tolerated dose: clinical endpoint for a
bygone era?. Targ Oncol. 2009;4(2):143–147.
[27] Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are
correlated with clinical benefit in patients with unresectable/
metastatic gastrointestinal stromal tumors. JCO. 2009;27(19):
3141–3147.
[28] Widmer N, Decosterd L, Csajka C, et al. Imatinib plasma levels:
correlation with clinical benefit in GIST patients. Br J Cancer.
2010;102(7):1198–1199.
[29] Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of
patients receiving imatinib for chronic myeloid leukemia. N Engl
J Med. 2006;355(23):2408–2417.
[30] Marisi G, Cucchetti A, Ulivi P, et al. Ten years of sorafenib in hep-
atocellular carcinoma: Are there any predictive and/or prognostic
markers? WJG. 2018;24(36):4152–4163.
[31] Camma C, Cabibbo G, Petta S, et al. Cost-effectiveness of sorafe-
nib treatment in field practice for patients with hepatocellular
carcinoma. Hepatology (Baltimore, MD). 2013;57(3):1046–1054.
[32] Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib dose escalation in the
treatment of advanced hepatocellular carcinoma. Oncology. 2012;
82(2):119–125.
[33] Reiss KA, Yu S, Mamtani R, et al. Starting dose of sorafenib for
the treatment of hepatocellular carcinoma: a retrospective, multi-
institutional study. JCO. 2017;35(31):3575–3581.
[34] Paolella GA, Boyd AD, Wirth SM, et al. Adherence to oral anti-
cancer medications: evolving interprofessional roles and pharma-
cist workforce considerations. Pharmacy (Basel, Switzerland).
2018;6(1):23.
[35] Abdel-Rahman O, Lamarca A. Development of sorafenib-related
side effects in patients diagnosed with advanced hepatocellular
carcinoma treated with sorafenib: a systematic-review and meta-
analysis of the impact on survival. Expert Rev Gastroenterol
Hepatol. 2017;11(1):75–83.
[36] Diaz-Gonzalez A, Sanduzzi-Zamparelli M, Sapena V, et al.
Systematic review with meta-analysis: the critical role of dermato-
logical events in patients with hepatocellular carcinoma treated
with sorafenib. Aliment Pharmacol Ther. 2019;49(5):482–491.
[37] Rimola J, Diaz-Gonzalez A, Darnell A, et al. Complete response
under sorafenib in patients with hepatocellular carcinoma: rela-
tionship with dermatologic adverse events. Hepatology
(Baltimore, MD). 2018;67(2):612–622.
8 T. A. LABEUR ET AL.
